| Species |
Human |
| Protein Construction |
Endostatin (Ala1571-Lys1754)
Accession # P39060 |
|
| Purity |
> 97% as analyzed by SDS-PAGE |
| Endotoxin Level |
< 1 EU/μg of protein by gel clotting method |
| Biological Activity |
Determined by Endothelial Cell Tube Formation. The cells treated with 10 μg/ml Endostatin showed significant anti-angiogenesis effect. |
| Expression System |
P. pastoris |
| Theoretical Molecular Weight |
20.2 kDa |
| Formulation |
Lyophilized from a sterile filtered solution in 17 mM citric-phosphate buffer, pH 6.2. |
| Reconstitution |
It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in ddH?O up to 100 μg/ml. |
| Storage & Stability |
Upon receiving, this product remains stable for up to 6 months at lower than -70°C. Upon reconstitution, the product should be stable for up to 1 week at 4°C or up to 3 months at -20°C. For long term storage it is recommended that a carrier protein (example 0.1% BSA) be added. Avoid repeated freeze-thaw cycles. |
| Target Background |
Endostatin is a cleaved product of the carboxyl-terminal domain of collagen XVIII. It functions as an anti-angiogenic cytokine that is expressed in various organs especially with high levels in liver, lung, and kidney. Endostatin inhibits angiogenesis by blocking the pro-angiogenic activities of VEGF and FGF-basic. In-vitro studies have shown endostatin blocks the proliferation and organization of endothelial cells into new blood vessels. In animal studies endostatin inhibited angiogenesis and growth of both primary tumors and secondary metastasis. |
| Synonyms |
Endostatin |
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.
